CY1116103T1 - Υποκατεστημενα παραγωγα 1,2,3,4-τετραϋδροϊσοκινολινης - Google Patents
Υποκατεστημενα παραγωγα 1,2,3,4-τετραϋδροϊσοκινολινηςInfo
- Publication number
- CY1116103T1 CY1116103T1 CY20151100188T CY151100188T CY1116103T1 CY 1116103 T1 CY1116103 T1 CY 1116103T1 CY 20151100188 T CY20151100188 T CY 20151100188T CY 151100188 T CY151100188 T CY 151100188T CY 1116103 T1 CY1116103 T1 CY 1116103T1
- Authority
- CY
- Cyprus
- Prior art keywords
- substituted
- tetrahydroisoquinoline derivatives
- compounds
- preparation
- pharmaceutical compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/18—Aralkyl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Abstract
Η εφεύρεση σχετίζεται με νέα παράγωγα 1,2,3,4-τετραϋδροϊσοκινολίνης του γενικού χημικού τύπου (I), όπου τα R1, R2, R3 και Χ είναι όπως ορίζονται στις αξιώσεις, και με τη χρήση τους ως δραστικά συστατικά στην παρασκευή φαρμακευτικών συνθέσεων. Η εφεύρεση αφορά επίσης σχετικές αποδόσεις που περιλαμβάνουν διαδικασίες για την παρασκευή των ενώσεων, των φαρμακευτικών συνθέσεων που περιλαμβάνουν μια ή περισσότερες εξ' αυτών των ενώσεων και μεθόδους θεραπείας που περιλαμβάνουν τη χορήγηση των εν λόγω ενώσεων σε κάποιο θηλαστικό.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP2004002020 | 2004-03-01 | ||
EP05804734.1A EP1751111B1 (en) | 2004-03-01 | 2005-02-23 | Substituted 1,2,3,4-tetrahydroisoquinoline derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1116103T1 true CY1116103T1 (el) | 2017-02-08 |
Family
ID=34960649
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20151100188T CY1116103T1 (el) | 2004-03-01 | 2015-02-20 | Υποκατεστημενα παραγωγα 1,2,3,4-τετραϋδροϊσοκινολινης |
Country Status (24)
Country | Link |
---|---|
US (2) | US7763638B2 (el) |
EP (1) | EP1751111B1 (el) |
JP (1) | JP4094050B2 (el) |
KR (1) | KR100848747B1 (el) |
CN (1) | CN1926109B (el) |
AR (1) | AR047823A1 (el) |
AU (1) | AU2005250077B2 (el) |
BR (1) | BRPI0508263B8 (el) |
CA (1) | CA2557163C (el) |
CY (1) | CY1116103T1 (el) |
DK (1) | DK1751111T3 (el) |
ES (1) | ES2533389T3 (el) |
HR (1) | HRP20150371T1 (el) |
IL (1) | IL177798A (el) |
MY (1) | MY144992A (el) |
NO (1) | NO337299B1 (el) |
NZ (1) | NZ550216A (el) |
PL (1) | PL1751111T3 (el) |
PT (1) | PT1751111E (el) |
RU (1) | RU2378257C2 (el) |
SI (1) | SI1751111T1 (el) |
TW (1) | TWI301129B (el) |
WO (1) | WO2005118548A1 (el) |
ZA (1) | ZA200606974B (el) |
Families Citing this family (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2378257C2 (ru) * | 2004-03-01 | 2010-01-10 | Актелион Фармасьютиклз Лтд | Замещенные производные 1,2,3,4-тетрагидроизохинолина |
EP1998774A1 (en) * | 2006-03-15 | 2008-12-10 | Actelion Pharmaceuticals Ltd. | Tetrahydroisoquinoline derivatives to enhance memory function |
JP2009533419A (ja) * | 2006-04-11 | 2009-09-17 | アクテリオン ファーマシューティカルズ リミテッド | 新規スルホンアミド化合物 |
JP2009535324A (ja) * | 2006-04-26 | 2009-10-01 | アクテリオン ファーマシューティカルズ リミテッド | 新規なピラゾロ−テトラヒドロピリジン誘導体 |
AU2007272854B2 (en) | 2006-07-14 | 2013-08-01 | Merck Sharp & Dohme Corp. | Bridged diazepan orexin receptor antagonists |
PE20081229A1 (es) | 2006-12-01 | 2008-08-28 | Merck & Co Inc | Antagonistas de receptor de orexina de diazepam sustituido |
AU2007337659A1 (en) * | 2006-12-22 | 2008-07-03 | Actelion Pharmaceuticals Ltd. | 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives |
AR064561A1 (es) * | 2006-12-28 | 2009-04-08 | Actelion Pharmaceuticals Ltd | Derivados de 2-aza-biciclo[3.1.0]hexano y su uso en la preparacion de un medicamento para el tratamiento de enfermedades relacionadas con disfunciones generales del sistema de la orexina. |
WO2008122513A1 (en) | 2007-04-04 | 2008-10-16 | F. Hoffmann-La Roche Ag | Heterocycles as orexin antagonists |
US8263586B2 (en) | 2007-05-18 | 2012-09-11 | Merck Sharp & Dohme Corp. | OXO bridged diazepan orexin receptor antagonists |
EP2150115B1 (en) | 2007-05-23 | 2013-09-18 | Merck Sharp & Dohme Corp. | Cyclopropyl pyrrolidine orexin receptor antagonists |
EP2152690B1 (en) | 2007-05-23 | 2012-01-11 | Merck Sharp & Dohme Corp. | Pyridyl piperidine orexin receptor antagonists |
CZ302135B6 (cs) * | 2007-07-09 | 2010-11-10 | Zentiva, A. S. | Zpusob výroby 5-[2-cyklopropyl-1-(2-fluorfenyl)-2-oxoethyl]-4, 5, 6, 7-tetrahydrothieno[3,2-c]pyridin-2-yl acetátu (prasugrelu) |
PE20091010A1 (es) * | 2007-10-10 | 2009-08-08 | Actelion Pharmaceuticals Ltd | Derivados de tetrahidroquinolina |
JP5100298B2 (ja) * | 2007-10-11 | 2012-12-19 | 株式会社トクヤマ | 光学活性α−スルホニルオキシカルボン酸アミド誘導体及びその製造方法 |
WO2009079637A1 (en) * | 2007-12-18 | 2009-06-25 | Concert Pharmaceuticals, Inc. | Tetrahydroisoquinoline derivatives |
ES2375334T3 (es) * | 2007-12-28 | 2012-02-28 | Actelion Pharmaceuticals Ltd. | Compuesto de 3,4-dihidro-1h-isoquinolina trisubstituida, procedimiento para su preparación y su uso. |
HUE028226T2 (en) * | 2007-12-28 | 2016-12-28 | Actelion Pharmaceuticals Ltd | A process for preparing an enantiomeric trisubstituted 3,4-dihydroisoquinoline derivative |
AU2009259494A1 (en) | 2008-06-16 | 2009-12-23 | F. Hoffmann-La Roche Ag | Heteroaromatic monoamides as orexinin receptor antagonists |
US20110105514A1 (en) * | 2008-06-25 | 2011-05-05 | Hamed Aissaoui | 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine compounds |
CN101402643B (zh) * | 2008-11-11 | 2012-11-28 | 上海现代制药股份有限公司 | 一种适于工业生产的普拉格雷的制备方法 |
KR20110091581A (ko) | 2008-12-02 | 2011-08-11 | 글락소 그룹 리미티드 | N-{[1r,4s,6r-3-(2-피리디닐카르보닐)-3-아자비시클로[4.1.0]헵트-4-일]메틸}-2-헤테로아릴아민 유도체 및 그의 용도 |
WO2010064212A1 (en) | 2008-12-05 | 2010-06-10 | Actelion Pharmaceuticals Ltd | Method for obtaining an optically pure 1,2,3,4 tetrahydro-isoquinoline derivative |
GB0823467D0 (en) | 2008-12-23 | 2009-01-28 | Glaxo Group Ltd | Novel Compounds |
WO2010095106A1 (en) | 2009-02-20 | 2010-08-26 | Actelion Pharmaceuticals Ltd | Solid forms of ( 2r) -2- { ( is ) -6, 7 -dimethoxy- 1- [2- (4-triflu0r0methyl-phenyl) -ethyl] -3, 4-dihydr0-1h -isoquinolin-2-yl} -n-methyl-2-phenyl-acetamide hydrochloride |
WO2010122151A1 (en) | 2009-04-24 | 2010-10-28 | Glaxo Group Limited | 3 -azabicyclo [4.1.0] heptanes used as orexin antagonists |
TW201105635A (en) | 2009-06-30 | 2011-02-16 | Actelion Pharmaceuticals Ltd | Process for the preparation of an enantiomerically pure trisubstituted 1,2,3,4-tetrahydroisoquinoline derivative |
WO2011005636A1 (en) * | 2009-07-09 | 2011-01-13 | Merck Sharp & Dohme Corp. | Tetrahydronapthyridine orexin receptor antagonists |
EP2470525A1 (en) | 2009-08-24 | 2012-07-04 | Glaxo Group Limited | Piperidine derivatives used as orexin antagonists |
EP2470523A1 (en) | 2009-08-24 | 2012-07-04 | Glaxo Group Limited | 5-methyl-piperidine derivatives as orexin receptor antagonists for the treatment of sleep disorder |
CZ2009686A3 (cs) | 2009-10-19 | 2011-04-27 | Zentiva, K. S | Zpusob prípravy (1S)-6,7-dimethoxy-1-[2-(4-trifluormethylfenyl)ethyl]-1,2,3,4-tetrahydroisochinolinu |
PL2491038T3 (pl) | 2009-10-23 | 2016-10-31 | Dwupodstawione oktahydropirolo[3,4-c]pirole jako modulatory receptora oreksyny | |
CZ2009791A3 (cs) | 2009-11-25 | 2011-06-01 | Zentiva, K. S. | Krystalická a amorfní forma hydrochloridu (2R)-2-{(1S)-6,7-dimethoxy-1-[2-(4-trifluoromethyl-fenyl)-ethyl]-3,4-dihydro-1H-isochinolin-2-yl}-N-methyl-2-fenyl-acetamidu (almorexantu) a zpusob jejich prípravy |
CZ302637B6 (cs) | 2010-01-05 | 2011-08-10 | Zentiva, K. S | Zpusob prípravy 6,7-dimethoxy-1-[2-(4-trifluormethylfenyl)ethyl]-3,4-dihydroisochinolinu |
EP2402322A1 (en) | 2010-07-02 | 2012-01-04 | Actelion Pharmaceuticals Ltd. | 1,2,3,4-tetrahydroisoquinoline derivative and its use as orexin receptor antagonist |
TW201209037A (en) | 2010-08-24 | 2012-03-01 | Actelion Pharmaceuticals Ltd | Proline sulfonamide derivatives as orexin receptor antagonists |
PT2626350E (pt) | 2010-09-22 | 2015-08-03 | Eisai R&D Man Co Ltd | Composto de ciclopropano |
EP2638008B1 (en) | 2010-11-10 | 2015-07-01 | Actelion Pharmaceuticals Ltd | Lactam derivatives useful as orexin receptor antagonists |
WO2012085852A1 (en) | 2010-12-22 | 2012-06-28 | Actelion Pharmaceuticals Ltd | 3,8-diaza-bicyclo[4.2.0]oct-8-yl amides |
WO2012089607A1 (en) | 2010-12-28 | 2012-07-05 | Glaxo Group Limited | Novel compounds with a 3a-azabicyclo [4.1.0] heptane core acting on orexin receptors |
WO2012089606A1 (en) | 2010-12-28 | 2012-07-05 | Glaxo Group Limited | Azabicyclo [4.1.0] hept - 4 - yl derivatives as human orexin receptor antagonists |
JP5987005B2 (ja) | 2011-02-18 | 2016-09-06 | アクテリオン ファーマシューティカルズ リミテッドActelion Pharmaceuticals Ltd | オレキシン拮抗薬として有用な新規なピラゾール及びイミダゾール誘導体 |
WO2012114252A1 (en) | 2011-02-21 | 2012-08-30 | Actelion Pharmaceuticals Ltd | Novel indole and pyrrolopyridine amides |
WO2012135465A2 (en) * | 2011-04-01 | 2012-10-04 | Indiana University Research And Technology Corporation | Treatment of glaucoma |
WO2013050938A1 (en) | 2011-10-04 | 2013-04-11 | Actelion Pharmaceuticals Ltd | 3,7-diazabicyclo[3.3.1]nonane and 9-oxa-3,7-diazabicyclo[3.3.1]nonane derivatives |
AR088352A1 (es) | 2011-10-19 | 2014-05-28 | Merck Sharp & Dohme | Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina |
CN103917538B (zh) | 2011-11-08 | 2016-08-24 | 埃科特莱茵药品有限公司 | 2-(1,2,3-***-2-基)苯甲酰胺及3-(1,2,3-***-2-基)吡啶酰胺衍生物 |
RU2014136339A (ru) | 2012-02-07 | 2016-03-27 | Иолас Терапьютикс, Инк. | Замещенные пролины/пиперидины как антагонисты орексиновых рецепторов |
US9440982B2 (en) | 2012-02-07 | 2016-09-13 | Eolas Therapeutics, Inc. | Substituted prolines/piperidines as orexin receptor antagonists |
EP2647377A1 (en) | 2012-04-06 | 2013-10-09 | Sanofi | Use of an h3 receptor antagonist for the treatment of alzheimer's disease |
SI2855453T1 (sl) | 2012-06-04 | 2017-05-31 | Actelion Pharmaceuticals Ltd. | Benzimidazol-prolinski derivati |
BR112015007516A2 (pt) | 2012-10-10 | 2017-07-04 | Actelion Pharmaceuticals Ltd | antagonistas do receptor de orexina que são derivados de [orto bi-(hetero-)aril]-[2-(meta bi-(hetero-)aril)- pirrolidin-1-il]-metanona |
CA2902135A1 (en) * | 2013-03-12 | 2014-09-18 | Actelion Pharmaceuticals Ltd | Azetidine amide derivatives as orexin receptor antagonists |
UA119151C2 (uk) | 2013-12-03 | 2019-05-10 | Ідорсія Фармасьютікалз Лтд | КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА |
MY179862A (en) | 2013-12-03 | 2020-11-18 | Idorsia Pharmaceuticals Ltd | Crystalline form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists |
LT3077391T (lt) | 2013-12-04 | 2018-10-25 | Idorsia Pharmaceuticals Ltd | Benzimidazolo prolino darinių panaudojimas |
ES2901418T3 (es) | 2014-08-13 | 2022-03-22 | Eolas Therapeutics Inc | Difluoropirrolidinas como moduladores del receptor de orexina |
CN107810006B (zh) | 2014-10-23 | 2021-03-30 | 卫材R&D管理有限公司 | 用于治疗失眠的组合物 |
SG11201803191VA (en) * | 2015-10-29 | 2018-05-30 | Univ Tsukuba | Morphinan derivative and medical usage thereof |
KR20180107232A (ko) | 2016-02-12 | 2018-10-01 | 아스트라제네카 아베 | 오렉신 수용체 조정제로서의 할로-치환된 피페리딘 |
JP7066622B2 (ja) | 2016-03-10 | 2022-05-13 | ヤンセン ファーマシューティカ エヌ.ベー. | オレキシン-2受容体アンタゴニストを用いてうつ病を治療する方法 |
KR101671008B1 (ko) * | 2016-04-13 | 2016-12-01 | 한국과학기술원 | TNP(N2-(m-Trifluorobenzyl), N6-(p-nitrobenzyl)purine) 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 식욕억제용 약학적 조성물 |
EP3454857A1 (en) | 2016-05-10 | 2019-03-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of autoimmune inflammatory diseases |
CN110117271A (zh) * | 2018-02-06 | 2019-08-13 | 中国科学院上海药物研究所 | 四氢异喹啉类化合物、其制备方法、包含此类化合物的药物组合物及其用途 |
WO2020007964A1 (en) | 2018-07-05 | 2020-01-09 | Idorsia Pharmaceuticals Ltd | 2-(2-azabicyclo[3.1.0]hexan-1-yl)-1h-benzimidazole derivatives |
WO2020007977A1 (en) | 2018-07-06 | 2020-01-09 | Idorsia Pharmaceuticals Ltd | 7-trifluoromethyl-[1,4]diazepan derivatives |
WO2020099511A1 (en) | 2018-11-14 | 2020-05-22 | Idorsia Pharmaceuticals Ltd | Benzimidazole-2-methyl-morpholine derivatives |
WO2023218023A1 (en) | 2022-05-13 | 2023-11-16 | Idorsia Pharmaceuticals Ltd | Thiazoloaryl-methyl substituted cyclic hydrazine-n-carboxamide derivatives |
CN117126134A (zh) * | 2022-05-20 | 2023-11-28 | 中国科学院上海药物研究所 | 新型四氢异喹啉类化合物、其制备方法、包含此类化合物的药物组合物及其用途 |
Family Cites Families (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3480714A (en) | 1966-02-07 | 1969-11-25 | Ciba Geigy Corp | N-substituted isoquinolines as antiprotozoal agents |
DD204917A1 (de) | 1981-12-31 | 1983-12-14 | Gerhard Kempter | Verfahren zur herstellung phenylsubstituierter und benzkondensierter cycloalkylaminoacetanilide |
DE3419642A1 (de) | 1984-05-25 | 1985-11-28 | Boehringer Mannheim Gmbh, 6800 Mannheim | Verfahren und reagenz zur vollenzymatischen bestimmung von harnstoff |
JPS6153268A (ja) | 1984-08-24 | 1986-03-17 | Hokuriku Seiyaku Co Ltd | アントラニルアミド誘導体 |
DD261158A1 (de) | 1987-01-08 | 1988-10-19 | Univ Halle Wittenberg | Verfahren zur herstellung von 2-aminoalkyl-3,4-dihydro-4-oxo-7h-pyrrolo 2.3-d pyrimidinen |
DD258817A1 (de) | 1987-01-19 | 1988-08-03 | Univ Halle Wittenberg | Verfahren zur herstellung von 2-(aminoalkyl) -pyrimido-4,5'-5,4 pyrrolo 3,2-f 1,4 thiazepinderivaten |
KR100220538B1 (ko) | 1991-01-11 | 1999-09-15 | 뮈쉘 쥐르밀 | 아크리딘 유도체 |
JPH07267961A (ja) | 1994-03-30 | 1995-10-17 | Taisho Pharmaceut Co Ltd | ベンゾフロ[3,2−dピリミジン−4−オン誘導体 |
US6184381B1 (en) | 1995-12-06 | 2001-02-06 | Japan Science & Technology Corp. | Process for preparing optically active compounds |
DE69726889T2 (de) | 1996-08-02 | 2004-10-21 | Scripps Research Inst | Hypothalamus-spezifische polypeptide |
JPH1095766A (ja) | 1996-09-19 | 1998-04-14 | Sanwa Kagaku Kenkyusho Co Ltd | アセトアミド誘導体、及びその用途 |
AU716151B2 (en) | 1996-11-27 | 2000-02-17 | Pfizer Inc. | Apo B-secretion/MTP inhibitory amides |
AR016817A1 (es) | 1997-08-14 | 2001-08-01 | Smithkline Beecham Plc | Derivados de fenilurea o feniltiourea, procedimiento para su preparacion, coleccion de compuestos, compuestos intermediarios, composicion farmaceutica,metodo de tratamiento y uso de dichos compuestos para la manufactura de un medicamento |
US6372757B1 (en) | 1998-05-08 | 2002-04-16 | Smithkline Beecham P.L.C. | Phenylurea and phenylthio urea derivatives |
WO2000029399A1 (en) | 1998-11-12 | 2000-05-25 | Boehringer Ingelheim (Canada) Ltd. | Antiherpes compounds |
GB9827467D0 (en) | 1998-12-15 | 1999-02-10 | Zeneca Ltd | Chemical compounds |
GB9914015D0 (en) | 1999-06-17 | 1999-08-18 | Zeneca Ltd | Chemical compounds |
ATE274512T1 (de) | 1999-02-12 | 2004-09-15 | Smithkline Beecham Plc | Phenylharnstoffe und phenylthioharnstoffe als orexinrezeptorantagonisten |
WO2000047576A1 (en) | 1999-02-12 | 2000-08-17 | Smithkline Beecham Plc | Cinnamide derivatives as orexin-1 receptors antagonists |
WO2000047284A2 (en) | 1999-02-12 | 2000-08-17 | Smithkline Beecham P.L.C. | Novel use of orexin receptor antagonists |
US6596730B1 (en) | 1999-02-12 | 2003-07-22 | Smithkline Beecham P.L.C. | Phenyl urea and phenyl thiourea derivatives |
GB9914025D0 (en) | 1999-06-17 | 1999-08-18 | Zeneca Ltd | Chemical compounds |
WO2001002368A1 (en) | 1999-07-06 | 2001-01-11 | Vertex Pharmaceuticals Incorporated | N-heterocyclic derivatives with neuronal activity |
AU6615300A (en) | 1999-07-30 | 2001-02-19 | Board Of Trustees Of The Leland Stanford Junior University | Hypocretin and hypocretin receptors in regulation of sleep and related disorders |
US6319710B1 (en) | 1999-08-23 | 2001-11-20 | Decode Genetics Ehf. | Human narcolepsy gene |
US6410712B1 (en) | 1999-10-25 | 2002-06-25 | Decode Genetics Ehf. | Human narcolepsy gene |
WO2001040304A1 (en) | 1999-12-01 | 2001-06-07 | Smithkline Beecham Corporation | Monkey orexin 2 receptor |
WO2001040259A2 (en) | 1999-12-02 | 2001-06-07 | Smithkline Beecham Corporation | Monkey orexin 1 receptor |
US20020064814A1 (en) | 1999-12-07 | 2002-05-30 | Ellis Catherine E. | Dog orexin 1 receptor |
KR20070087103A (ko) * | 2000-03-14 | 2007-08-27 | 액테리온 파마슈티칼 리미티드 | 1,2,3,4-테트라하이드로이소퀴놀린 유도체 |
AU2001251306A1 (en) | 2000-04-04 | 2001-10-15 | Siegel, Jerome M. | Treatment of sleep disorders with hypocretin-1 |
AU779266B2 (en) | 2000-05-11 | 2005-01-13 | Banyu Pharmaceutical Co., Ltd. | N-acyltetrahydroisoquinoline derivatives |
DE60110066T2 (de) | 2000-06-16 | 2006-02-02 | Smithkline Beecham P.L.C., Brentford | Piperidine zur verwendung als orexinrezeptorantagonisten |
WO2002044172A1 (en) | 2000-11-28 | 2002-06-06 | Smithkline Beecham P.L.C. | Morpholine derivatives as antagonists of orexin receptors |
US20020166135A1 (en) | 2000-12-20 | 2002-11-07 | Waleh Nahid S. | Modulators of the hypocretin system and methods of screening therefor |
WO2002051232A2 (en) | 2000-12-27 | 2002-07-04 | Actelion Pharmaceuticals Ltd. | Novel benzazepines and related heterocyclic derivatives |
ES2299567T3 (es) | 2001-05-05 | 2008-06-01 | Smithkline Beecham Plc | N-aroilaminas ciclicas. |
WO2002089800A2 (en) | 2001-05-05 | 2002-11-14 | Smithkline Beecham P.L.C. | N-aroyl cyclic amine derivatives as orexin receptor antagonists |
GB0115862D0 (en) | 2001-06-28 | 2001-08-22 | Smithkline Beecham Plc | Compounds |
JP4399256B2 (ja) | 2001-06-28 | 2010-01-13 | スミスクライン ビーチャム ピー エル シー | オレキシン受容体アンタゴニストとしてのn−アロイル環状アミン誘導体 |
GB0124463D0 (en) | 2001-10-11 | 2001-12-05 | Smithkline Beecham Plc | Compounds |
GB0126292D0 (en) | 2001-11-01 | 2002-01-02 | Smithkline Beecham Plc | Compounds |
GB0127145D0 (en) | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Compounds |
GB0130388D0 (en) | 2001-12-19 | 2002-02-06 | Smithkline Beecham Plc | Compounds |
GB0130341D0 (en) | 2001-12-19 | 2002-02-06 | Smithkline Beecham Plc | Compounds |
GB0130393D0 (en) | 2001-12-19 | 2002-02-06 | Smithkline Beecham Plc | Compounds |
GB0130335D0 (en) | 2001-12-19 | 2002-02-06 | Smithkline Beecham Plc | Compounds |
AU2003227614B2 (en) | 2002-04-26 | 2008-06-26 | F. Hoffmann-La Roche Ag | Isoquinoline derivatives |
AU2003262963A1 (en) | 2002-08-29 | 2004-03-19 | The Regents Of The University Of California | Hypocretin administration as a treatment for obesity |
EP1539747B1 (en) | 2002-09-18 | 2006-11-02 | Glaxo Group Limited | N-aroyl cyclic amines as orexin receptor antagonists |
GB0225944D0 (en) | 2002-11-06 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
GB0225938D0 (en) | 2002-11-06 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
GB0225884D0 (en) | 2002-11-06 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
WO2004052876A1 (en) | 2002-12-12 | 2004-06-24 | Janssen Pharmaceutica, N.V. | Substituted 4-phenyl-[1,3]-dioxanes |
CA2509215A1 (en) | 2002-12-13 | 2004-07-01 | Janssen Pharmaceutica N.V. | Method for identifying modulators of human orexin-2 receptor |
EP1611104B1 (en) * | 2003-03-26 | 2009-07-01 | Actelion Pharmaceuticals Ltd. | Tetrahydroisoquinolyl acetamide derivatives for use as orexin receptor antagonists |
RU2378257C2 (ru) * | 2004-03-01 | 2010-01-10 | Актелион Фармасьютиклз Лтд | Замещенные производные 1,2,3,4-тетрагидроизохинолина |
EP1998774A1 (en) | 2006-03-15 | 2008-12-10 | Actelion Pharmaceuticals Ltd. | Tetrahydroisoquinoline derivatives to enhance memory function |
JP2009535324A (ja) | 2006-04-26 | 2009-10-01 | アクテリオン ファーマシューティカルズ リミテッド | 新規なピラゾロ−テトラヒドロピリジン誘導体 |
-
2005
- 2005-02-23 RU RU2006134624/04A patent/RU2378257C2/ru active
- 2005-02-23 US US10/598,449 patent/US7763638B2/en active Active
- 2005-02-23 DK DK05804734.1T patent/DK1751111T3/en active
- 2005-02-23 BR BRPI0508263-3 patent/BRPI0508263B8/pt active IP Right Grant
- 2005-02-23 AU AU2005250077A patent/AU2005250077B2/en active Active
- 2005-02-23 WO PCT/EP2005/001879 patent/WO2005118548A1/en active Application Filing
- 2005-02-23 ES ES05804734.1T patent/ES2533389T3/es active Active
- 2005-02-23 JP JP2007501172A patent/JP4094050B2/ja active Active
- 2005-02-23 PL PL05804734T patent/PL1751111T3/pl unknown
- 2005-02-23 NZ NZ550216A patent/NZ550216A/en unknown
- 2005-02-23 CA CA2557163A patent/CA2557163C/en active Active
- 2005-02-23 PT PT58047341T patent/PT1751111E/pt unknown
- 2005-02-23 SI SI200531944T patent/SI1751111T1/sl unknown
- 2005-02-23 KR KR1020067020299A patent/KR100848747B1/ko active IP Right Grant
- 2005-02-23 EP EP05804734.1A patent/EP1751111B1/en active Active
- 2005-02-23 CN CN200580006491XA patent/CN1926109B/zh active Active
- 2005-02-28 AR ARP050100745A patent/AR047823A1/es unknown
- 2005-02-28 MY MYPI20050816A patent/MY144992A/en unknown
- 2005-03-01 TW TW094106070A patent/TWI301129B/zh active
-
2006
- 2006-08-21 ZA ZA200606974A patent/ZA200606974B/xx unknown
- 2006-08-31 IL IL177798A patent/IL177798A/en active IP Right Grant
- 2006-09-26 NO NO20064347A patent/NO337299B1/no unknown
-
2010
- 2010-06-15 US US12/815,605 patent/US20100256182A1/en not_active Abandoned
-
2015
- 2015-02-20 CY CY20151100188T patent/CY1116103T1/el unknown
- 2015-03-30 HR HRP20150371TT patent/HRP20150371T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1116103T1 (el) | Υποκατεστημενα παραγωγα 1,2,3,4-τετραϋδροϊσοκινολινης | |
CY1122863T1 (el) | Φαρμακευτικη συνθεση που περιεχει γλυκοπυρρολικο και εναν αγωνιστη βητα2 αδρενοϋποδοχεα | |
CY1110419T1 (el) | Τρικυκλικες ενωσεις με βαση το 1,6-διυδρο-1,3,5,6-tetpaaza-as-ινδακενιο και φαρμακευτικες συνθεσεις που τις περιεχουν ως αναστολεις της ενζυμικης ενεργοτητας της ικκ | |
CY1108094T1 (el) | Κινολινικα παραγωγα ως αναστολεις φωσφοδιεστερασης | |
CY1115199T1 (el) | Κυτταροτοξικοι παραγοντες που περιεχουν νεα παραγωγα τομαϋμυκινης και η θεραπευτικη τους χρηση | |
CY1110332T1 (el) | Παραγωγα βενζιμιδαζολης, συνθεσεις που τα περιεχουν, παρασκευη αυτων και χρηση τους | |
CY1122349T1 (el) | Παραγωγα 1-benzyλ-3-υδροξυμεθυλινδαζολης και χρηση αυτων στη θεραπεια νοσων που βασιζονται στην εκφραση των mcp-1, cxcr1 και ρ40 | |
CY1105362T1 (el) | Παραγωγα σουλφοναμιδιου, η παρασκευη τους και η εφαρμογη αυτων ως φαρμακα | |
CY1107851T1 (el) | Παραγωγα πυρολλο-πυριδινης και η χρηση τους ως ανταγωνιστων crth2 | |
DK2314582T3 (da) | Heterocykliske forbindelser som antivirusmidler | |
ECSP066314A (es) | Derivados piridilo y su uso como agentes terapéuticos | |
TR200302242T2 (tr) | Protein kinaz önleyicileri olarak pirolopirimidinler | |
CY1113323T1 (el) | Ενωσεις τετραϋδροφουρο[3,4-d]διοξολανιου για χρηση στη θεραπεια ιικων μολυνσεων και καρκινου | |
BR0113838A (pt) | Derivados de n-fenil-2-pirimidina-amina | |
NO20070224L (no) | 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav | |
BRPI0418251B8 (pt) | fosfonatos, monofosfonamidatos, bisfosfonamidatos, e, composição farmacêutica os compreendendo | |
NO20050088L (no) | Kationisk substituerte difenylazefidinoner, fremgangsmate for deres fremstilling, medikamenter inneholdende nevnte forbindelser og anvendelse derav | |
PT1404347E (pt) | Nucleosidos 4'-substituidos para o tratamento de doencas mediadas pelo virus da hepatite c | |
CY1112708T1 (el) | [1η-ινδολο-5-υλο)-ετεροαρυλοξυ]-(1-αζα-δικυκλο[3.3.1]εννεανια ως χολινεργικοι συνδετες του ν-achr για την θεραπεια των ψυχωτικων και νευροεκφυλιστικων διαταραχων | |
BRPI0418939A (pt) | derivados de nicotinamida e sua utilização como agentes terapêuticos | |
UY30316A1 (es) | Derivados sustituidos de benzamidas, nicotinamidas, propanamidas, acetamidas y carboxamidas n-(2-(piperidin-1-ilmetil)ciclohexil)sustituidas, procesos de preparacion, composiciones conteniéndolos y aplicaciones | |
BRPI0412851A (pt) | benzamidazóis de n-metila-substituìdos | |
DE60003863D1 (de) | Dioxocyclopentylhydroxamsäure | |
SE0401342D0 (sv) | Therapeutic compounds | |
CY1114140T1 (el) | Ενωσεις 4-πυριδινονης και η χρηση αυτων για τον καρκινο |